Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial

NCT05607329 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Ovarian Cancer

Interventions

PROCEDURE: Secondary cytoreduction
DRUG: Chemotherapy

Sponsor

Women's Hospital School Of Medicine Zhejiang University